NCT01534182 - Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) | Biotech Hunter

Enrollment

298

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

Fingolimod

0.5 mg orally once a day

DRUG

Interferon beta - 1a (IFN)

44 mcg subcutaneously three times a week

DRUG

Glatiramer acetate (GA)

20 mg subcutaneously once a day

Trial Locations (26)

119992

Novartis Investigative Site, Moscow

127018

Novartis Investigative Site, Moscow

150030

Novartis Investigative Site, Yaroslavl

163045

Novartis Investigative Site, Arkhangelsk

170036

Novartis Investigative Site, Tver'

197376

Novartis Investigative Site, Saint Petersburg

214019

Novartis Investigative Site, Smolensk

305007

Novartis Investigative Site, Kursk

308007

Novartis Investigative Site, Belgorod

350086

Novartis Investigative Site, Krasnodar

410030

Novartis Investigative Site, Saratov

420021

Novartis Investigative Site, Kazan'

430032

Novartis Investigative Site, Saransk

432063

Novartis Investigative Site, Ulyanovsk

450000

Novartis Investigative Site, Ufa

603076

Novartis Investigative Site, Nizhny Novgorod

603126

Novartis Investigative Site, N.Novgorod

603155

Novartis Investigative Site, Nizhny Novgorod

610014

Novartis Investigative Site, Kirov

614990

Novartis Investigative Site, Perm

625048

Novartis Investigative Site, Tyumen

628012

Novartis Investigative Site, Khanty-Mansiysk

630087

Novartis Investigative Site, Novosibirsk

634050

Novartis Investigative Site, Tomsk

650066

Novartis Investigative Site, Kemerovo

656024

Novartis Investigative Site, Barnaul